Lipocine Inc

NASDAQ:LPCN

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 13 full-time employees. The company went IPO on 2014-03-21. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The company has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.